Tango Therapeutics (TNGX) Common Equity (2020 - 2025)
Historic Common Equity for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $160.0 million.
- Tango Therapeutics' Common Equity fell 3016.93% to $160.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year decrease of 3016.93%. This contributed to the annual value of $199.5 million for FY2024, which is 2117.32% down from last year.
- Tango Therapeutics' Common Equity amounted to $160.0 million in Q3 2025, which was down 3016.93% from $135.0 million recorded in Q2 2025.
- Tango Therapeutics' Common Equity's 5-year high stood at $365.4 million during Q3 2021, with a 5-year trough of $5.0 million in Q1 2021.
- Over the past 5 years, Tango Therapeutics' median Common Equity value was $247.7 million (recorded in 2024), while the average stood at $222.9 million.
- Per our database at Business Quant, Tango Therapeutics' Common Equity soared by 2028489.89% in 2021 and then tumbled by 4551.12% in 2025.
- Quarter analysis of 5 years shows Tango Therapeutics' Common Equity stood at $344.7 million in 2021, then fell by 27.64% to $249.5 million in 2022, then rose by 1.46% to $253.1 million in 2023, then fell by 21.17% to $199.5 million in 2024, then dropped by 19.79% to $160.0 million in 2025.
- Its Common Equity was $160.0 million in Q3 2025, compared to $135.0 million in Q2 2025 and $166.8 million in Q1 2025.